Business context and reporting period
This is ZIOPHARM Oncology, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2012, filed May 3, 2012. The filing identifies ZIOPHARM—not Alaunos Therapeutics, Inc.—as the registrant, so the company and period should be verified against the requested filing metadata. ZIOPHARM was a development-stage biopharmaceutical company focused on cancer drug candidates; it had no approved products and reported minimal collaboration revenue.
Key financial metrics
Amounts below are in U.S. dollars; financial statement amounts are in thousands unless stated otherwise.
| Metric | Q1 2012 | Q1 2011 / comparison |
|---|---|---|
| Collaboration revenue | $0.2 million | $0.067 million; up 199% |
| Research and development expense | $14.0 million | $24.6 million; down 43% |
| General and administrative expense | $4.8 million | $3.4 million; up 45% |
| Net loss | $24.5 million | $39.0 million |
| Net loss per share, basic and diluted | $0.32 | $0.65 |
| Net cash used in operating activities | $25.9 million | $8.2 million |
| Cash and cash equivalents, quarter-end | $128.0 million | $104.7 million at Dec. 31, 2011 |
| Working capital, quarter-end | $124.5 million | $92.7 million at Dec. 31, 2011 |
| Total liabilities, quarter-end | $43.2 million | $36.5 million at Dec. 31, 2011 |
Operating loss was $18.6 million, compared with $27.9 million in Q1 2011. No product sales or meaningful operating margin were reported. The filing reports no debt balance; liabilities included $25.2 million of warrant liabilities. Total assets were $140.9 million and stockholders’ equity was $97.7 million at March 31, 2012.
Material changes versus the prior comparable period
- R&D expense fell $10.7 million year over year, principally because Q1 2011 included a one-time $17.5 million noncash charge for the Intrexon technology and channel partnership. Excluding that charge, Q1 2012 R&D expense increased $6.8 million, mainly from clinical-trial activity, headcount, and preclinical and manufacturing costs.
- G&A expense rose $1.5 million, primarily from higher contracted and employee-related costs.
- The net loss narrowed by $14.5 million. A lower noncash warrant revaluation loss contributed: $5.8 million in Q1 2012 versus $11.1 million in Q1 2011.
- Operating cash use increased by $17.7 million, including a $9.3 million prepayment to related party Intrexon for services expected within a year.
- A January 2012 public offering generated approximately $49.2 million net proceeds from 10,114,401 shares. Shares outstanding were 79,532,882 at quarter-end; 79,522,502 were reported outstanding as of April 23, 2012.
Outlook, management commentary, risks and unusual items
- Management expected existing cash resources to fund operations into the second half of 2013, but said additional financing would be needed for long-term clinical trials and product development. There were no committed additional capital sources; future equity financing could dilute shareholders.
- For the next 12 months, management forecast approximately $96.5 million of R&D expense and $21.8 million of G&A expense. These estimates were subject to substantial uncertainty.
- Key development plans included completing the Phase 3 PICASSO 3 trial of palifosfamide in soft-tissue sarcoma and initiating a Phase 3 small-cell lung cancer trial in the second half of 2012. Management cited expected PICASSO 3 full enrollment in Q2 2012 and anticipated progression-free-survival results late in the second half of 2012, conditional on enrollment; these were expectations, not guarantees.
- Material risks included clinical-trial delays or failure, regulatory approval uncertainty, dependence on third-party manufacturers and research organizations, early-stage Intrexon platform risks, intellectual-property disputes, and the need for future financing. The company cautioned that trial costs and timelines could differ materially from forecasts.
- After quarter-end, the company entered a CRO agreement for the planned SCLC Phase 3 trial with $18.1 million of future milestone payments. It also signed additional office leases with obligations of approximately $493,000 through August 2016 and $383,000 through October 2018. These items were not included in the quarter-end contractual-obligations table.
- Quarter-end contractual obligations totaled $17.2 million, including $10.1 million of contract milestone payments, largely tied to the PPD CRO agreement. Timing depends on factors including enrollment, trial outcomes, and regulatory requirements.
- The $5.8 million warrant fair-value loss was noncash; liability-classified warrants were valued using a Binomial/Monte Carlo model. Management reported effective disclosure controls and no material change in internal control over financial reporting. No material legal proceedings were identified as of March 31, 2012.
Important facts for investors to verify
- Confirm that the requested issuer is ZIOPHARM Oncology, Inc.; the filing does not identify Alaunos Therapeutics, Inc. as the registrant.
- Check subsequent clinical-trial progress and whether the stated enrollment and result expectations were achieved.
- Assess actual cash burn against the second-half-2013 runway estimate, including the post-quarter SCLC CRO commitment and other development costs.
- Review future financing needs, potential dilution, and the outstanding warrant overhang and valuation sensitivity.
- Verify reported Q1 2012 share counts and the terms and proceeds of the January offering against the company’s subsequent filings.